Valuation: Shanghai Hile Bio-Technology Co., Ltd.

Capitalization 4B 578M 485M 444M 423M 784M 52.4B 815M 5.16B 2.04B 25.18B 2.17B 2.12B 90.15B P/E ratio 2023
107x
P/E ratio 2024 26.6x
Enterprise value 3.5B 506M 425M 388M 370M 686M 45.86B 713M 4.52B 1.79B 22.04B 1.9B 1.86B 78.89B EV / Sales 2023
28.9x
EV / Sales 2024 14.9x
Free-Float
48.49%
Yield 2023
0.27%
Yield 2024 1.13%
More valuation ratios * Estimated data
Dynamic Chart
Jan. 02 Shanghai Hile Bio-Technology Subsidiary to Buy 51% Stake in Seven Dental Clinics MT
Dec. 18 Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of an additional 41% stake in Shaanxi Reshine Biotech Co. Ltd. from Maylion Management Limited. CI
Dec. 17 Indonesia Approves Shanghai Hile Bio-Technology Subsidiary's Bone Grafting Material MT
Nov. 29 Shanghai Hile Bio-Technology Co., Ltd. agreed to acquire an additional 41% stake in Shaanxi Reshine Biotech Co. Ltd. for approximately CNY 400 million. CI
25-10-28 Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-11 Hile Bio-Technology Unit's Registration for Bone Repair Material Accepted in China MT
25-08-27 Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-21 Shanghai Hile Bio-Technology Co., Ltd. announces Annual dividend, payable on July 15, 2025 CI
25-04-21 Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-21 Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-12-02 Shanghai Haoyuan Venture Capital Development Co., Ltd. completed the acquisition of 76.07% stake in Yangling Jinhai Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd.. CI
24-11-11 Shanghai Haoyuan Venture Capital Development Co., Ltd. agreed to acquire 76.07% stake in Yangling Jinhai Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for approximately CNY 245 million. CI
24-10-30 Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
More news
1 day+1.31%
1 week-7.02%
Current month-16.33%
1 month-16.20%
3 months-21.98%
6 months-28.55%
Current year-10.98%
More quotes
1 week 5.2
Extreme 5.2
5.48
1 month 5.2
Extreme 5.2
7.19
Current year 5.2
Extreme 5.2
7.19
1 year 5.2
Extreme 5.2
8.01
3 years 5.2
Extreme 5.2
12.05
5 years 5.2
Extreme 5.2
19.6
10 years 5.2
Extreme 5.2
54.03
More quotes
Manager TitleAgeSince
Chief Executive Officer 61 2023-07-31
Director of Finance/CFO 56 2024-05-22
Chief Executive Officer 41 2021-05-23
Director TitleAgeSince
Director/Board Member 58 2024-11-26
Chairman 65 2022-05-19
Director/Board Member 71 2017-12-13
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.31%-7.02%-25.51%-52.20% 511M
-0.09%+1.89%-25.74%-20.84% 56.1B
-1.47%+0.32%+115.54%+88.11% 12.34B
+2.72%+7.91%-14.01%+9.97% 4.37B
+0.43%0.00%+10.78%+20.93% 3.47B
-0.83%-4.85%+134.34%+39.30% 2.44B
-2.30%+23.72%+118.87%+226.10% 2.1B
+1.06%-1.59%-34.82%-6.06% 1.56B
+0.10%+0.84%+16.43%-5.14% 1.26B
+0.12%-0.23%+20.11%+2.61% 1.21B
Average +0.11%+4.04%+31.60%+30.28% 8.54B
Weighted average by Cap. -0.16%+2.93%+6.02%+6.63%
See all sector performances

Financials

2023 2024
Net sales 241M 34.77M 29.22M 26.7M 25.44M 47.2M 3.15B 49.07M 311M 123M 1.52B 130M 128M 5.43B 271M 39.15M 32.89M 30.06M 28.64M 53.14M 3.55B 55.25M 350M 138M 1.71B 147M 144M 6.11B
Net income 62.87M 9.08M 7.63M 6.97M 6.64M 12.33M 824M 12.81M 81.15M 32.12M 396M 34.06M 33.36M 1.42B 171M 24.73M 20.78M 18.99M 18.09M 33.56M 2.24B 34.89M 221M 87.45M 1.08B 92.73M 90.83M 3.86B
Net Debt -82.2M -11.87M -9.98M -9.12M -8.69M -16.12M -1.08B -16.75M -106M -41.99M -518M -44.53M -43.61M -1.85B -499M -72.15M -60.62M -55.41M -52.78M -97.94M -6.54B -102M -645M -255M -3.15B -271M -265M -11.26B
More financial data * Estimated data
Logo Shanghai Hile Bio-Technology Co., Ltd.
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Company’s products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndrome’76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.
Employees
366
More about the company
Date Price Change Volume
26-02-09 5.430 ¥ +1.31% 25,153,150
26-02-06 5.360 ¥ +2.68% 34,571,680
26-02-05 5.220 ¥ -2.61% 47,404,210
26-02-04 5.360 ¥ +1.90% 76,510,510
26-02-03 5.260 ¥ -9.93% 8,685,500

End-of-day quote Shanghai S.E., February 08, 2026

More quotes
  1. Stock Market
  2. Equities
  3. 603718 Stock